Studiet viste, at behandling med fondaparinux ikke er enoxaparin underlegen (forekomst af VTE henholdsvis 3, 9% og 4, 1%).
Treatment with fondaparinux was demonstrated to be non-inferior to enoxaparin (VTE rates 3.9% and 4.1%, respectively).